" class="no-js "lang="en-US"> Anixa Biosciences - Medtech Alert
Thursday, March 28, 2024
Anixa Biosciences | Pharmtech Focus

Anixa Biosciences

About Anixa Biosciences

Anixa Biosciences
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

Related Story

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial

August 16 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa”) a biotechnology company focused on the treatment and prevention of cancer […]

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

March 31 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and […]